Effects of Metformin on the Gut Microbiota in Obesity and Type 2 Diabetes Mellitus

References

• Pearson ER. Type 2 diabetes: a multifaceted disease. Diabetologia. 2019;62(7):1107–1112. doi:10.1007/s00125-019-4909-y
   PubMedGoogle Scholar
• Caspard H, Jabbour S, Hammar N, Fenici P, Sheehan JJ, Kosiborod M. Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA: an analysis of the NHANES surveys from 1999 to 2014. Diabetes Obes Metab. 2018;20(3):667–671. doi:10.1111/dom.13143
   PubMedGoogle Scholar
• Coughlan KA, Valentine RJ, Ruderman NB, Saha AK. AMPK activation: a therapeutic target for type 2 diabetes?. Diabetes Metab Syndr Obes. 2014;7:241–253.
   PubMedGoogle Scholar
• Foretz M, Hébrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010;120(7):2355–2369.
   PubMed Web of Science ®Google Scholar
• Chandel NS, Avizonis D, Reczek CR, et al. Are metformin doses used in murine cancer models clinically relevant?. Cell Metab. 2016;23(4):569–570.
   PubMed Web of Science ®Google Scholar
• Pollak M. The effects of metformin on gut microbiota and the immune system as research frontiers. Diabetologia. 2017;60(9):1662–1667.
   PubMed Web of Science ®Google Scholar
• Burcelin R, Serino M, Chabo C, Blasco-Baque V, Amar J. Gut microbiota and diabetes: from pathogenesis to therapeutic perspective. Acta Diabetol. 2011;48(4):257–273.
   PubMed Web of Science ®Google Scholar
• Ley RE, Hamady M, Lozupone C, et al. Evolution of mammals and their gut microbes. Science. 2008;320(5883):1647–1651.
   PubMed Web of Science ®Google Scholar
• Bäckhed F. Host responses to the human microbiome. Nutr Rev. 2012;70(Suppl 1):S14–S17.
   PubMedGoogle Scholar
• Larsen N, Vogensen FK, van den Berg FW, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010;5(2):e9085.
   PubMed Web of Science ®Google Scholar
• Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60. doi:10.1038/nature11450
   PubMed Web of Science ®Google Scholar
• Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498(7452):99–103. doi:10.1038/nature12198
   PubMed Web of Science ®Google Scholar
• Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57(6):1470–1481.
   PubMed Web of Science ®Google Scholar
• Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes. 2012;3(4):279–288. doi:10.4161/gmic.19625
   PubMed Web of Science ®Google Scholar
• De Vadder F, Kovatcheva-Datchary P, Goncalves D, et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell. 2014;156(1–2):84–96. doi:10.1016/j.cell.2013.12.016
   PubMed Web of Science ®Google Scholar
• Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165(6):1332. doi:10.1016/j.cell.2016.05.041
   PubMed Web of Science ®Google Scholar
• Yang XQ, Li LL, Wang Y. The association between the metabolites of intestional flora and diabetes mellitus in mice. Chin J Microecol. 2011;23(2):134–136.
   Google Scholar
• Ryan PM, Stanton C, Caplice NM. Bile acids at the cross-roads of gut microbiome-host cardiometabolic interactions. Diabetol Metab Syndr. 2017;9:102.
   PubMed Web of Science ®Google Scholar
• Fava S. Glucagon-like peptide 1 and the cardiovascular system. Curr Diabetes Rev. 2014;10(5):302–310.
   PubMedGoogle Scholar
• Pavlidis P, Powell N, Vincent RP, Ehrlich D, Bjarnason I, Hayee B. Systematic review: bile acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence?. Aliment Pharmacol Ther. 2015;42(7):802–817.
   PubMed Web of Science ®Google Scholar
• Ridlon JM, Harris SC, Bhowmik S, Kang DJ, Hylemon PB. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes. 2016;7(1):22–39. doi:10.1080/19490976.2015.1127483
   PubMed Web of Science ®Google Scholar
• Winston JA, Theriot CM. Impact of microbial derived secondary bile acids on colonization resistance against clostridium difficile in the gastrointestinal tract. Anaerobe. 2016;41:44–50.
   PubMed Web of Science ®Google Scholar
• Weingarden AR, Chen C, Zhang N, et al. Ursodeoxycholic acid inhibits clostridium difficile spore germination and vegetative growth, and prevents the recurrence of ileal pouchitis associated with the infection. J Clin Gastroenterol. 2016;50(8):624–630. doi:10.1097/MCG.0000000000000427
   PubMed Web of Science ®Google Scholar
• Sonne DP, van Nierop FS, Kulik W, Soeters MR, Vilsbøll T, Knop FK. Postprandial plasma concentrations of individual bile acids and FGF-19 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2016;101(8):3002–3009. doi:10.1210/jc.2016-1607
   PubMed Web of Science ®Google Scholar
• Zhang F, Yuan W, Wei Y, et al. The alterations of bile acids in rats with high-fat diet/streptozotocin-induced type 2 diabetes and their negative effects on glucose metabolism. Life Sci. 2019;229:80–92.
   PubMedGoogle Scholar
• Shin NR, Lee JC, Lee HY, et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut. 2014;63(5):727–735. doi:10.1136/gutjnl-2012-303839
   PubMed Web of Science ®Google Scholar
• Lee H, Ko G. Effect of metformin on metabolic improvement and gut microbiota. Appl Environ Microbiol. 2014;80(19):5935–5943. doi:10.1128/AEM.01357-14
   PubMed Web of Science ®Google Scholar
• Bornstein S, Moschetta M, Kawano Y, et al. Metformin affects cortical bone mass and marrow adiposity in diet-induced obesity in male mice. Endocrinology. 2017;158(10):3369–3385.
   PubMedGoogle Scholar
• Lee H, Lee Y, Kim J, et al. Modulation of the gut microbiota by metformin improves metabolic profiles in aged obese mice. Gut Microbes. 2018;9(2):155–165.
   PubMed Web of Science ®Google Scholar
• Wang J-H, Bose S, Shin NR, Chin Y-W, Choi YH, Kim H. Pharmaceutical impact of and metformin combination on high-fat-diet-induced metabolic disorders: link to intestinal microbiota and metabolic endotoxemia. Front Endocrinol (Lausanne). 2018;9:620.
   PubMed Web of Science ®Google Scholar
• Zheng J, Li H, Zhang X, et al. Prebiotic mannan-oligosaccharides augment the hypoglycemic effects of metformin in correlation with modulating gut microbiota. J Agric Food Chem. 2018;66(23):5821–5831. doi:10.1021/acs.jafc.8b00829
   PubMed Web of Science ®Google Scholar
• Ji S, Wang L, Li L. Effect of metformin on short-term high-fat diet-induced weight gain and anxiety-like behavior and the gut microbiota. Front Endocrinol (Lausanne). 2019;10:704. doi:10.3389/fendo.2019.00704
   PubMed Web of Science ®Google Scholar
• Brandt A, Hernández-Arriaga A, Kehm R, et al. Metformin attenuates the onset of non-alcoholic fatty liver disease and affects intestinal microbiota and barrier in small intestine. Sci Rep. 2019;9(1):6668.
   PubMedGoogle Scholar
• Ryan PM, Patterson E, Carafa I, et al. Metformin and dipeptidyl peptidase-4 inhibitor differentially modulate the intestinal microbiota and plasma metabolome of metabolically dysfunctional mice. Can J Diabetes. 2020;44(2):146–155.e2. doi:10.1016/j.jcjd.2019.05.008
   PubMedGoogle Scholar
• Chung E, Elmassry MM, Kottapalli P, et al. Metabolic benefits of annatto-extracted tocotrienol on glucose homeostasis, inflammation, and gut microbiome. Nutr Res. 2020;77:97–107. doi:10.1016/j.nutres.2020.04.001
   PubMed Web of Science ®Google Scholar
• Ahmadi S, Razazan A, Nagpal R, et al. Metformin reduces aging-related leaky gut and improves cognitive function by beneficially modulating gut microbiome/goblet cell/mucin axis. J Gerontol a Biol Sci Med Sci. 2020;75(7):e9–e21.
   PubMed Web of Science ®Google Scholar
• Chen C, You LJ, Huang Q, et al. Modulation of gut microbiota by mulberry fruit polysaccharide treatment of obese diabetic db/db mice. Food Funct. 2018;9(7):3732–3742.
   PubMed Web of Science ®Google Scholar
• Zhang W, Xu JH, Yu T, Chen QK. Effects of berberine and metformin on intestinal inflammation and gut microbiome composition in db/db mice. Biomed Pharmacother. 2019;118:109131.
   PubMed Web of Science ®Google Scholar
• Gao K, Yang R, Zhang J, et al. Effects of Qijian mixture on type 2 diabetes assessed by metabonomics, gut microbiota and network pharmacology. Pharmacol Res. 2018;130:93–109. doi:10.1016/j.phrs.2018.01.011
   PubMed Web of Science ®Google Scholar
• Chen LC, Fan ZY, Wang HY, Wen DC, Zhang SY. Effect of polysaccharides from adlay seed on anti-diabetic and gut microbiota. Food Funct. 2019;10(7):4372–4380.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhao Y, Xu J, et al. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci Rep. 2015;5:14405.
   PubMed Web of Science ®Google Scholar
• Li Q, He R, Zhang F, Zhang J, Lian S, Liu H. Combination of oligofructose and metformin alters the gut microbiota and improves metabolic profiles, contributing to the potentiated therapeutic effects on diet-induced obese animals. Front Endocrinol (Lausanne). 2019;10:939.
   PubMedGoogle Scholar
• Liu G, Bei J, Liang L, Yu G, Li L, Li Q. Stachyose improves inflammation through modulating gut microbiota of high-fat diet/streptozotocin-induced type 2 diabetes in rats. Mol Nutr Food Res. 2018;62(6):e1700954.
   PubMed Web of Science ®Google Scholar
• Liu G, Liang L, Yu G, Li Q. Pumpkin polysaccharide modifies the gut microbiota during alleviation of type 2 diabetes in rats. Int J Biol Macromol. 2018;115:711–717.
   PubMed Web of Science ®Google Scholar
• Cui HX, Zhang LS, Luo Y, Yuan K, Huang ZY, Guo Y. A purified anthraquinone-glycoside preparation from rhubarb ameliorates type 2 diabetes mellitus by modulating the gut microbiota and reducing inflammation. Front Microbiol. 2019;10:1423.
   PubMedGoogle Scholar
• Liu Y, Wang C, Li J, et al. Phellinus linteus polysaccharide extract improves insulin resistance by regulating gut microbiota composition. FASEB J. 2020;34(1):1065–1078.
   PubMed Web of Science ®Google Scholar
• Khat-Udomkiri N, Toejing P, Sirilun S, Chaiyasut C, Lailerd N. Antihyperglycemic effect of rice husk derived xylooligosaccharides in high-fat diet and low-dose streptozotocin-induced type 2 diabetic rat model. Food Sci Nutr. 2020;8(1):428–444.
   PubMedGoogle Scholar
• Wang JH, Bose S, Lim SK, et al. Houttuynia cordata facilitates metformin on ameliorating insulin resistance associated with gut microbiota alteration in OLETF rats. Genes (Basel). 2017;8(10):239.
   PubMedGoogle Scholar
• Zhang M, Feng R, Yang M, et al. Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats. BMJ Open Diabetes Res Care. 2019;7(1):e000717.
   PubMedGoogle Scholar
• Hiel S, Gianfrancesco MA, Rodriguez J, et al. Link between gut microbiota and health outcomes in inulin -treated obese patients: lessons from the food4gut multicenter randomized placebo-controlled trial. Clin Nutr. 2020;S0261-5614(20):30160–30166.
   Google Scholar
• Ejtahed HS, Tito RY, Siadat SD, et al. Metformin induces weight loss associated with gut microbiota alteration in non-diabetic obese women: a randomized double-blind clinical trial. Eur J Endocrinol. 2019;180(3):165–176.
   PubMedGoogle Scholar
• Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015;528(7581):262–266.
   PubMed Web of Science ®Google Scholar
• Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017;23(7):850–858.
   PubMed Web of Science ®Google Scholar
• de la Cuesta-zuluaga J, Mueller NT, Corrales-Agudelo V, et al. Metformin is associated with higher relative abundance of mucin-degrading akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. Diabetes Care. 2017;40(1):54–62.
   PubMed Web of Science ®Google Scholar
• Sun L, Xie C, Wang G, et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med. 2018;24(12):1919–1929.
   PubMed Web of Science ®Google Scholar
• Hung F, Nilholm C, Roth B, et al. Anthropometric and metabolic improvements in human type 2 diabetes after introduction of an okinawan-based nordic diet are not associated with changes in microbial diversity or SCFA concentrations. Int J Food Sci Nutr. 2018;69(6):729–740.
   PubMedGoogle Scholar
• Barengolts E, Green SJ, Eisenberg Y, et al. Gut microbiota varies by opioid use, circulating leptin and oxytocin in African American men with diabetes and high burden of chronic disease. PLoS One. 2018;13(3):e0194171.
   PubMed Web of Science ®Google Scholar
• Zhang F, Wang M, Yang J, et al. Response of gut microbiota in type 2 diabetes to hypoglycemic agents. Endocrine. 2019;66(3):485–493.
   PubMed Web of Science ®Google Scholar
• Chávez-Carbajal A, Pizano-Zárate ML, Hernández-Quiroz F, et al. Characterization of the gut microbiota of individuals at different T2D stages reveals a complex relationship with the host. Microorganisms. 2020;8(1):94.
   PubMed Web of Science ®Google Scholar
• Deng GH, Cha YL, Zhang GX, et al. Comparison of human and animal fecal microbiota with Illumina sequencing of 16S rRNA tags. Ecol Sci. 2014;33(5):851–857.
   Google Scholar
• Ahmad A, Yang W, Chen G, et al. Analysis of gut microbiota of obese individuals with type 2 diabetes and healthy individuals. PLoS One. 2019;14(12):e0226372.
   PubMedGoogle Scholar
• Sedighi M, Razavi S, Navab-Moghadam F, et al. Comparison of gut microbiota in adult patients with type 2 diabetes and healthy individuals. Microb Pathog. 2017;111:362–369.
   PubMed Web of Science ®Google Scholar
• Peng W, Huang J, Yang J, et al. Integrated 16S rRNA sequencing, metagenomics, and metabolomics to characterize gut microbial composition, function, and fecal metabolic phenotype in non-obese type 2 diabetic goto-kakizaki rats. Front Microbiol. 2019;10:3141.
   PubMed Web of Science ®Google Scholar
• Bibbò S, Ianiro G, Giorgio V, et al. The role of diet on gut microbiota composition. Eur Rev Med Pharmacol Sci. 2016;20(22):4742–4749.
   PubMed Web of Science ®Google Scholar
• Elbere I, Kalnina I, Silamikelis I, et al. Association of metformin administration with gut microbiome dysbiosis in healthy volunteers. PLoS One. 2018;13(9):e0204317.
   PubMed Web of Science ®Google Scholar
• Bryrup T, Thomsen CW, Kern T, et al. Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study. Diabetologia. 2019;62(6):1024–1035.
   PubMed Web of Science ®Google Scholar
• Ma W, Chen J, Meng Y, Yang J, Cui Q, Zhou Y. Metformin alters gut microbiota of healthy mice: implication for its potential role in gut microbiota homeostasis. Front Microbiol. 2018;9:1336.
   PubMed Web of Science ®Google Scholar
• Zhou ZY, Ren LW, Zhan P, Yang HY, Chai DD, Yu ZW. Metformin exerts glucose-lowering action in high-fat fed mice via attenuating endotoxemia and enhancing insulin signaling. Acta Pharmacol Sin. 2016;37(8):1063–1075.
   PubMed Web of Science ®Google Scholar
• Carter D, Howlett HC, Wiernsperger NF, Bailey CJ. Differential effects of metformin on bile salt absorption from the jejunum and ileum. Diabetes Obes Metab. 2003;5(2):120–125.
   PubMedGoogle Scholar
• Napolitano A, Miller S, Nicholls AW, et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One. 2014;9(7):e100778.
   PubMed Web of Science ®Google Scholar
• Zhang X, Shen D, Fang Z, et al. Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One. 2013;8(8):e71108.
   PubMed Web of Science ®Google Scholar
• Cani PD, de Vos WM. Next-generation beneficial microbes: the case of akkermansia muciniphila. Front Microbiol. 2017;8:1765.
   PubMed Web of Science ®Google Scholar
• Delzenne NM, Cani PD, Everard A, Neyrinck AM, Bindels LB. Gut microorganisms as promising targets for the management of type 2 diabetes. Diabetologia. 2015;58(10):2206–2217.
   PubMed Web of Science ®Google Scholar
• Horakova O, Kroupova P, Bardova K, et al. Metformin acutely lowers blood glucose levels by inhibition of intestinal glucose transport. Sci Rep. 2019;9(1):6156.
   PubMedGoogle Scholar
• Morita Y, Nogami M, Sakaguchi K, et al. Enhanced release of glucose into the intraluminal space of the intestine associated with metformin treatment as revealed by [(18)F]fluorodeoxyglucose PET-MRI. Diabetes Care. 2020;43(8):1796–1802.
   PubMedGoogle Scholar
• Bauer PV, Duca FA, Waise TMZ, et al. Metformin alters upper small intestinal microbiota that impact a glucose-SGLT1-sensing glucoregulatory pathway. Cell Metab. 2018;27(1):101–117.e5.
   PubMedGoogle Scholar